EU4Health Programme (EU4H) – Action Grants 2024 (HERA) – 2024

Objectives

• To enhance crisis preparedness and response for future health emergencies in relation to medical countermeasures, with a focus on priority pathogens with pandemic potential. It implements the EU4Health Programme’s general objective of improving the availability, accessibility and affordability of crisisrelevant products
• To foster innovation and support development of nextgeneration respiratory PPE that overcomes the limitations outlined above and result in increased availability of enhanced medical countermeasures for pandemic preparedness and response
• To support improved manufacturing technologies and processes that allow for a more effective, less expensive, easier to scale-up, more sustainable and cleaner production of medicines in the Union, and to support the Union’s pharmaceutical industry to be better able to respond to public health need s in the context of health emergencies and critical medicines’ shortages
• To support the policy priority to be better prepared to respond to serious cross-border health threats

Among financed actions

• The creation of a European Hub for public health relevant vaccine development
• The development of support for or innovations targeting manufacturing of APIs, their intermediates and/or excipients
• To contribute to increasingly sophisticated enhancements to chemical and/or biological processes or decreasing the production of polluting agents
• The development of novel manufacturing processes and technologies, and novel industrial manufacturing and facility designs
• The development and further characterisation of broadspectrum antivirals targeting identified HERA priority viral families

Eligibility

• Be a legal person
• Be a public or private entity
• Be established in one of the eligible countries:
  • EU Member States (including overseas countries and territories)
  • Non-EU states: listed EEA countries and countries associated to the EU4Health Programme (list of participating countries)
• EU4H-2024-PJ-01-1:
  • Vaccine developers including publicly funded and industrial organisations
  • Proposals must be submitted by a consortium of at least 3 applicants
• EU4H-2024-PJ-01-2:
  • Legal entities active in the field of innovation and with adequate expertise in PPE, proven by experience in the sector (e.g. past development activities, academic research)
  • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants
• EU4H-2024-PJ-01-3:
  • Industrial economic operators, technology developers and applied research
    stakeholders capable of developing the mentioned manufacturing technologies and processes
  • Established legal entities with a clear track record of industrial innovation development
  • Technical expertise in the area of manufacturing technologies and/or processes relevant to the call.
  • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants
• EU4H-2024-PJ-01-4:
  • Private, academic and public bodies active and in the field of innovation and with proven expertise in development of antivirals
  • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants

Additional information

• Initial duration of the action:
  • EU4H-2024-PJ-01-1: 48 months
  •  EU4H-2024-PJ-01-2: 48 months
  •  EU4H-2024-PJ-01-3: between 24 and 48 months
  • EU4H-2024-PJ-01-4: 24 months
• Contact: HADEA-HP-CALLS@ec.europa.eu

Useful

Guidelines: Click here

Other call documents: Click here

Executive Agency website: Click here

More information: Click here

• Total budget of the call: 149 million euro
• Total budget of the topic:
  • EU4H-2024-PJ-01-1: 102 million euro
  •  EU4H-2024-PJ-01-2: 20 million euro
  •  EU4H-2024-PJ-01-3: 17 million euro
  • EU4H-2024-PJ-01-4: 10 million euro
• Amount of the grant:
  • EU4H-2024-PJ-01-1: 102 million euro
  • EU4H-2024-PJ-01-2: 5 million euro
  •  EU4H-2024-PJ-01-3: 5.6 million euro
  • EU4H-2024-PJ-01-4: 10 million euro
• Funding rate: 60% of the total eligible costs (80% for projects project of exceptional utility)